SHH Healthcare Drug Manufacturers - Specialty & Generic 600085.SS

Beijing Tongrentang Co., Ltd

$ 23.50 -1.84 %

Beijing Tongrentang Co., Ltd. is a pharmaceutical enterprise primarily focused on the research, development, manufacturing, and global distribution of traditional Chinese medicines (TCM). Its diverse product range includes various formulations such as classic pills, specialized powders, medicinal wines, capsules, oral solutions, and innovative dripping pills, often utilizing original powder preparations. These remedies address a wide array of health issues, including cardiovascular, cerebrovascular, and gynecological conditions, alongside the creation of new antidepressant drugs. The company markets its well-known products under established brand series like Angong Niuhuang, Tongren Niuhuang Qingxin, and Tongren Dahuoluo, as well as specific items such as Yufeng Ningxin dripping pills and Hemiplegia recovery pills. Based in Beijing, China, Beijing Tongrentang Co., Ltd. operates as a subsidiary of the broader China Beijing Tongrentang (Group) Co., Ltd.

CEO: Chaohua Zhang - https://www.tongrentanggf.com

Summary 30-Y Financials Dividend Analyst Key metrics Ownership / Senat
Price objectif

-

Recommandation

-

DCF

$ 43.43

Loading data...

600085.SS vs S&P500

Loading data...

No data available.

Quick ratio

2.25

suggests a healthy liquidity position, showing that the company can likely meet its short-term obligations.

P/E ratio

29.75

is considered reasonable, suggesting that the company has a valuation in line with its current profits.

EPS

0.79

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

7.87 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

5.32 %

generates a return higher than the cost of its capital, thereby creating value for its investors.

WACC

4.97

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

0.28

indicates that the company uses more equity than debt, suggesting prudent management.

Free cash flow per share

1.76

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

128.78 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
6 indicates moderate financial health
Altman score
3.93 indicates good financial health and low risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
1.68 indicates that the company has sufficient cash to cover its short-term debts
Debt Ratio
0.13 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.